Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.47 |
| ▸ | STK3 | Q13188 | 1/20 | 0.47 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.47 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.47 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488927 | 1.00 | HRH3 (0.56) | HRH3JAK2ROCK2PRKD3PRKCG | |
| SCHEMBL489636 | 0.89 | HRH3 (0.52) | HRH3JAK2ROCK2PRKD3PRKCG | |
| SCHEMBL489637 | 0.89 | HRH3 (0.52) | HRH3JAK2ROCK2PRKD3PRKCG | |
| SCHEMBL489262 | 0.84 | HRH3 (0.48) | HRH3JAK2ROCK2PRKD3PRKCG | |
| SCHEMBL489184 | 0.84 | HRH3 (0.60) | HRH3JAK2ROCK2PRKD3PRKCG | |
| SCHEMBL489264 | 0.84 | HRH3 (0.48) | HRH3JAK2ROCK2PRKD3PRKCG | |
| SCHEMBL489183 | 0.84 | HRH3 (0.60) | HRH3JAK2ROCK2PRKD3PRKCG | |
| SCHEMBL489494 | 0.84 | HRH3 (0.60) | HRH3JAK2ROCK2PRKD3PRKCG | |
| SCHEMBL489495 | 0.84 | HRH3 (0.60) | HRH3JAK2ROCK2PRKD3PRKCG | |
| SCHEMBL488977 | 0.83 | HRH3 (0.55) | HRH3JAK2ROCK2PRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311831-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | Abbott Laboratories (US) | 2011-04-20 | — | — | EP | claimed |
| EP-1620434-B1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LAB (US) | 2011-03-09 | — | — | EP | claimed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | claimed |
| US-20080119520-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | US | claimed |
| US-7094790-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-08-22 | — | — | US | claimed |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-12-09 | — | — | US | claimed |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | claimed |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2311831-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | Abbott Laboratories (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-1620434-B1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LAB (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-7807697-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080119520-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-7094790-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060142325-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-06-29 | — | — | US | disclosed |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | HRH3 1/4885JAK2 1232/4885ROCK2 4785/4885 |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | HRH3 1/4885JAK2 1249/4885ROCK2 4722/4885 |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | HRH4, HRH3, HRH2 | HRH3 2/4885JAK2 1145/4885ROCK2 3646/4885 |
| US-20060142325-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH2 | HRH3 1/4885JAK2 1249/4885ROCK2 4722/4885 |
| US-20080119520-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | HRH3 1/4885JAK2 1249/4885ROCK2 4722/4885 |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | HRH3, HRH4, HRH2 | HRH3 1/4885JAK2 1249/4885ROCK2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.